国产伊曲康唑（美扶）治疗174例浅部真菌病临床观察

应用美扶（伊曲康唑胶囊）200mg，每日2次，连服7天治疗手足癣100例及美扶200mg，每日1次，连服7天治疗体股癣74例，3周后观察疗效。结果显示美扶治疗手足癣的痊愈率及总有效率分别为49．49％和90．91％；体股癣则分别为73．33％和93．33％。美扶对体股癣及手足癣的真菌清除率均达到了96％。     

伊曲康唑治疗体股癣临床疗效观察

为了进一步观察伊曲康唑治疗体癣、股癣的疗效、耐受性及不良反应 ,我院皮肤科门诊从 1999年 3月～ 10月对10 7例采用伊曲康唑治疗的体股癣患者进行临床观察。现将随访到的 81例病人疗效报告如下。1　资料与方法1.1　病例选择　 81例体股癣患者均来自我院皮肤科门诊。其中体癣 2 3例 ,股癣 41例 ,体股癣并存 17例。所有病人服药前肝功能检查均正常。就诊前 4周内均未使用过皮质类固醇激素或其它抗生素、抗真菌药 ,治疗期间停用一切其它口服及外用药物。1.2　临床资料　见表 1。1.3　治疗方法　所有病人采用伊曲康唑 (西安杨森公司生产 ,商品…     

伊曲康唑短程疗法治疗体股癣60例疗效观察

我们于１９９６年７月～１９９７年１月采用伊曲康唑（商品名斯皮仁诺,西安杨森制药有限公司生产）短程疗法（２００ｍｇ／ｄ,连服７天）治疗体癣及股癣共６０例,效果满意,现将结果报告如下。临床资料６０例均为我科门诊病人,通过临床和真菌直接镜检或培养阳性的体癣...     

伊曲康唑(美扶)治疗皮肤浅部真菌病60例临床疗效观察

我科自2003年7-10月，采用伊曲康唑(商品名：美扶，天津力生制药厂)治疗60例皮肤浅部真菌病，取得较好的效果，现将临床观察结果总结报告如下。     

伊曲康唑治疗浅部真菌病

我们于 1998年 1月～ 1999年 9月应用伊曲康唑 (商品名斯皮仁诺 ,西安杨森制药有限公司生产 )治疗浅部真菌病10 1例 ,取得了满意疗效。现报告如下。临床资料　 10 1例均为临床症状典型 ,并经真菌直接镜检阳性确诊为浅部真菌病门诊病例。手癣 6例 ,足癣 2 2例(其中角化型 8例 ) ,体癣 12例 ,股癣 2 5例 ,花斑癣 3 6例。男 5 7例 ,女 44例 ;年龄 18～ 65岁 ;病程 1月～ 10年。　 [作者单位 ]福建省皮肤病性病防治院 ,福建福州　 31 0 0 0 9用药前血、尿常规正常 ,无肝肾疾病。 1月内未用过其它口服或外用抗真菌药物。除 3 6例花斑癣患者外 ,其…     

伊曲康唑短程疗法治疗体股癣40例

采用伊曲康唑２００ｍｇ,每日１次,连服７天治疗体股癣４０例。结果显示,疗后４周临床治愈率为５２．５％,总有效率为８５％,真菌治愈率为７７．５％。笔者认为此方法疗程短,见效快,副作用轻。     

国产伊曲康唑治疗体股癣多中心临床研究

为了验证国产伊曲康唑胶囊(四川成都倍特药业有限公司生产,商品名易启康)治疗浅部真菌病的临床疗效和安全性,我们组织上海市11家三级医院皮肤科于2002年4-6月对普通门诊的体股癣患者进行了多中心开放性临床研究。     

国产伊曲康唑治疗皮肤浅部真菌病216例疗效观察

为观察国产伊曲康唑（美扶）治疗浅部真菌病的疗效。选择216例皮肤浅部真菌病患者，均口服美扶治疗，其中手足癣组口服美扶200mg，bid，连服7天；其余各组口服美扶200mg，qd，连服7天。停药3周评价疗效。结果：手足癣、体股癣、花斑癣、马拉色菌毛囊炎、念珠菌性包皮龟头炎和念珠菌性阴道炎总有效率分别为94．12％、97．47％、95．65％、81．25％、100％、81．25％。国产伊曲康唑治疗浅部真菌病疗效好、经济而安全。     

国产伊曲康唑治疗108例浅部真菌病临床观察

我们于2004年10月～2005年3月使用成都倍特药业有限公司生产的易启康（伊曲康唑胶囊）治疗手足癣、体股癣等浅部真菌病108例，取得较满意疗效，现将结果报道如下。     

1%盐酸布替萘芬乳膏治疗体股癣、足癣疗效观察

目的：评价1％盐酸布替萘芬乳膏治疗体股癣、足癣的临床疗效和安全性。方法：采用多中心、随机、双盲、平行对照的方法．试验组外用1％盐酸布替萘芬乳膏,对照组外用1％联苯苄唑乳膏。结果：体股癣患者停药时试验组与对照组痊愈率分别为32．76％和38．98％。有效率分别为93．10％和94．92％;停药2周时,试验组与对照组痊愈率分别为62．07％和64．41％,有效率分别为93．10％和96．61％。足癣患者停药时．试验组与对照组痊愈率分别为29．31％和30．00％．有效率分别为89．66％和85．00％;停药2周时,试验组与对照组痊愈率分别为48．28％和43．33％．有效率分别为91．38％和86．67％。局部不良反应发生率,两试验组为5．13％;两对照组为4．17％。上述各项指标,两组比较差异无统计学意义。结论：1％盐酸布替萘芬乳膏治疗体股癣、足癣安全有效。     

股癣患者致病菌与足趾间分离皮肤癣菌的同源性分析

目的:探讨股癣患者足趾间分离的皮肤癣菌与股癣致病菌之间的关系。方法:对26例股癣患者进行趾间取材真菌镜检及培养。趾间与股部培养菌株如经鉴定相同,则进一步采用巢式PCR扩增真菌rDNA非转录间隔区(NTS)中Trs-1片段,检测基因多态性。结果:26例股癣患者中,19例足部培养阳性。其中,4例与股部分离菌株不同;15例与股部分离菌株相同,均为红色毛癣菌。进一步对15例两部位分离的共30株红色毛癣菌进行基因多态性检测,发现5例两部位菌株型别不一致。股部与趾间分离菌株不一致者共9例,占34.6%(9/26)。结论:不同部位皮肤癣菌感染可能为不同菌种或不同型别菌株的混合感染。本实验的发现有助于进一步了解皮肤癣菌感染的流行病学特征。     

美克治疗体股癣、手足癣、花斑癣和皮肤念珠菌病疗效观察

目的评价美克(1%联苯苄唑乳膏)治疗体股癣、手足癣、花斑癣和皮肤念珠菌病的临床疗效和安全性。方法采用多中心、随机、平行对照的方法,试验组外用美克,对照组外用欣欣(1%盐酸布替萘芬乳膏)。结果体股癣患者停药时试验组与对照组痊愈率分别为42.20%和39.45%,有效率分别为94.49%和91.74%;停药2w时,试验组与对照组痊愈率分别为85.32%和82.56%,有效率分别为97.24%和96.33%。手足癣停药时试验组与对照组痊愈率分别为39.87%和37.34%,有效率分别为85.54%和84.81%;停药2w时,试验组与对照组痊愈率分别为59.49%和58.22%,有效率分别为89.24%和86.70%。花斑癣患者停药时试验组与对照组痊愈率分别为50.72%和52.17%,有效率分别为79.71%和76.81%;停药2w时,试验组与对照组痊愈率分别为66.67%和63.76%,有效率分别为84.05%和81.16%。皮肤念珠菌病患者停药时试验组与对照组痊愈率分别为34.88%和39.53%,有效率分别为72.09%和76.74%;停药2w时,试验组与对照组痊愈率分别为65.11%和67.44%,有效率分别为88.37%和86.04%。局部不良反应发生率各试验组合计为5.27%;各对照组合计为5.54%。上述各项指标,各病种试验组与对照组比较差异均无统计学意义。结论美克治疗体股癣、手足癣、花斑癣和皮肤念珠菌病安全有效。     

Tinea capitis in early infancy treated with itraconazole: a pilot study

Background  Tinea capitis is the most common fungal infection of the scalp in childhood, but a very rare disorder in the first year of life.
Objective  To evaluate the efficacy, tolerability and safety of itraconazole in 7 children aged between 3 and 46 weeks (median: 36 weeks) suffering from tinea capitis caused by Microsporum canis .
Methods  Prospective case note study. In all patients KOH testing and fungal cultivation on Sabouraud dextrose agar were performed.
Results  7 patients (5 girls and 2 boys) were included in the period between 2001 and 2008. The causative etiologic agent was Microsporum canis in all children. The patients received itraconazole 5mg/kg bodyweight daily for 3 to 6 weeks with no clinically side effects being noted. In all patients clinical and mycological cure could be achieved.
Conclusion  Itraconazole proved to be a safe and effective treatment option for Microsporum canis induced tinea capitis in children in their first year of life.     

1%盐酸特比萘芬乳膏治疗浅部真菌感染的疗效观察

目的：观察1％盐酸特比萘芬乳膏治疗浅部真菌感染的疗效及安全性。方法：对门诊78例经临床及真菌镜检诊断为股癣，手足癣及花斑癣的病人，每天2次使用1％盐酸特比萘芬乳膏外搽，疗程2周，治疗开始及治疗结束2周后进行症状及体征评分和真菌学镜检，治疗结束随访时同时对病人进行满意度调查。共对随访资料完整的78例病人的治疗结果进行了总结。结果：1％盐酸特比萘芬乳膏治疗手足癣的总有效率为94．1％，对股癣总有效率为96％，对花斑癣总有效率为89．5％。病人总体满意度方面表示非常好和很好的比例为84．6％。没有记录到治疗有关的副作用。结论：1％盐酸特比萘芬乳膏治疗皮肤真菌感染具有很高的临床有效率及依从性，安全性高，值得推广为治疗皮肤表皮癣菌的一线用药。     

皮肤镜辅助诊断不典型泛发性体癣一例

患者,女,24岁.面、躯干、双上肢红斑、鳞屑伴痒3个月.皮肤科查体:面部、躯干、双上肢散在分布绿豆至黄豆大红斑,上有少许白色鳞屑,部分皮损中心破损结痂.皮肤镜检查提示可能存在真菌感染,建议行真菌检查.真菌涂片镜检:菌丝阳性;真菌培养为犬小孢子菌.诊断为体癣.经抗真菌治疗后痊愈,随访无复发.     

鲁比切克毛癣菌致体癣一例

【摘要】 患者男，54岁，右侧臀部红斑伴瘙痒半年，皮损逐渐扩大，出现脱屑。体检见右侧臀部红色斑片，覆散在鳞屑，边界清楚，边缘略高于皮面，鳞屑明显。真菌学检查：取皮屑行10% KOH直接镜检，见带有折光性的透明菌丝。皮屑真菌培养，培养物在形态学、生理学和遗传学上有以下几个方面特征：①沙氏葡萄糖琼脂培养基上菌落呈绒毛状，马铃薯葡萄糖培养基培养产红色色素，中央有紫红色色素颗粒形成；②小培养见梨形或棒状小分生孢子，圆柱状大分生孢子，丰富的节孢子；③尿素酶试验阳性，毛发穿孔试验阴性。取培养菌落提取DNA进行分子生物学鉴定，扩增菌株rDNA的ITS1-4区，测序结果与已知的鲁比切克毛癣菌或红色毛癣菌ITS1-ITS4片段序列进行比对，显示完全一致。分离菌株鉴定为鲁比切克毛癣菌。诊断：鲁比切克毛癣菌所致体癣。治疗：口服特比萘芬片0.25 g·kg-1·d-1，2周后皮损消退。     

Optimizing the therapeutic approach in tinea capitis of childhood with itraconazole

BACKGROUND: Tinea capitis is the most common dermatophytosis of childhood with increasing incidence. Whereas griseofulvin is considered by many as the mainstay of treatment, newer oral antifungal agents, including fluconazole, itraconazole and terbinafine have demonstrated higher efficacy, resulting in shorter treatment durations. OBJECTIVES: We aimed to determine the optimum regimen for the treatment of childhood tinea capitis with itraconazole. METHODS: A mycological culture outcome-dependent combination of a 28-day continuous and facultative additional 14-day courses with itraconazole was used in 42 children (20 girls; 22 boys) aged 12-140 months (mean 66) with tinea capitis due to Microsporum canis (n = 26) and Trichophyton violaceum (n = 16). The drug was given orally according to the patients' body weight (50 mg daily for < 20 kg; 100 mg daily for > or = 20 kg) over 4 weeks. Direct microscopy and fungal culture as a parameter for efficacy were repeated 2 weeks after termination of treatment. Assessment of efficacy was based on the evaluation of results from light microscopy and culture at 8 weeks after initiation of treatment, and in the case of a further positive mycological culture at 14 and 20 weeks, respectively. A positive fungal culture at these times resulted in an additional course for 2 weeks with the initially chosen itraconazole dosage. RESULTS: In 34 of 42 patients a single 4-week course of itraconazole resulted in a complete mycological cure of lesions as demonstrated by light microscopy and mycological culture. Four of 42 patients had to be treated by a second itraconazole course for 2 weeks, and four children received a third course of itraconazole for 2 weeks until all lesions showed negative direct microscopy and mycological culture. No abnormal haematological or biochemical results occurred. Apart from transient, completely reversible indigestion in two children, no side-effects were observed. CONCLUSIONS: A culture-based 28-day continuous therapeutic regimen plus facultative cultural outcome-dependent additional 14-day courses of a body weight-adapted dosage of itraconazole in tinea capitis due to M. canis and T. violaceum is discussed; this offers the advantage of an effective therapy with complete negative direct microscopy as well as negative cultural results, within a shorter active treatment period (cf. previous studies with continuous administration of itraconazole).     

Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete''s foot): a randomized, double-blind, placebo-controlled study

BACKGROUND: Tinea pedis is a common dermatophyte infection with frequent recurrences. Terbinafine (presently used as a 1-week topical treatment of tinea pedis) is now available in a novel topical solution (film-forming solution--FFS), developed to allow single application. OBJECTIVES: To demonstrate the efficacy and safety of terbinafine 1% FFS in a randomized, double-blind, placebo-controlled, phase III trial, and to determine relapse or re-infection rate of tinea pedis at 12 weeks. PATIENTS/METHODS: Fifty-four centres (27 in France; 27 in Germany) enrolled 273 evaluable patients (2 : 1 randomization). Patients applied terbinafine 1% FFS or placebo only once between, under and over the toes, soles and sides of both feet. Efficacy assessments included direct microscopy, mycological culture, and clinical signs and symptoms at baseline, and at weeks 1, 6 and 12 after the single drug application. RESULTS: Effective treatment (negative mycology plus absent/minimal symptoms) at week 6 in the terbinafine 1% FFS group was 63%; vehicle was 17% (P相似文献